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0To the Editor: Estimation of bleeding risk is a crucial step in the
anagement of patients with atrial fibrillation (AF). Three bleed-
ng risk–prediction schemes have been derived and validated
xclusively in AF populations: HEMORR2HAGES, HAS-
LED, and ATRIA (1,2). In the present analysis, the perfor-
ance of these 3 schemes was tested in the idraparinux arm of the
MADEUS trial (Evaluating the Use of SR34006 Compared to
arfarin or Acenocoumarol in Patients With Atrial Fibrillation) (3).
A total of 2,283 patients (67% men; age 70.1  9 years) were
andomized to the idraparinux arm. Overall, 74 major bleeding
vents, 346 any clinically relevant bleeding events, and 62 deaths
ccurred over 311  161 days of follow-up. Specific data for each
isk score are shown in Table 1.
The 3 scores demonstrated only modest discriminative ability
or all outcomes as reflected by the c-indexes in receiver-operating
haracteristic curve analysis. The ATRIA score presented
-indexes of 0.61 (95% confidence interval [CI]: 0.54 to 0.68), 0.56
95% CI: 0.53 to 0. 59), and 0.65 (95% CI: 0.58 to 0.73) for the
utcomes of major bleeding, any clinically relevant bleeding, and
The AMADEUS Cohort Stratified According to the ATRHAS-BLED, and HEMORR2HAGES Bleedin Risk–PredicTable 1
The A ADEUS Cohort Stratified Accor in
HAS-BLED, and HEMORR2HAGES Bleedin
Study N
Major Bleed
n
ATRIA
0 260 6
1 1,092 23
2 188 8
3 475 22
4 95 2
5 36 1
6 106 9
7 11 1
HAS-BLED
0 364 3
1 1,139 38
2 633 25
3 131 8
4 7 0
HEMORR2HAGES
0 992 20
1 867 34
2 311 14
3 65 4
4 5 0
AMADEUS  Evaluating the Use of SR34006 Compared to Warfarin o
and risk factors in atrial fibrillation; HAS-BLED  hypertension, abnorm
elderly, drugs/alcohol; HEMORR2HAGES  hepatic or renal disease, ethano
rebleeding, hypertension, anemia, genetic factors, excessive fall risk and stroeath, respectively. The HAS-BLED score demonstrated
-indexes of 0.60 (95% CI: 0.54 to 0.66), 0.61 (95% CI: 0.58 to
.65), and 0.62 (95% CI: 0.55 to 0.69) for the outcome of major
leeding, any clinically relevant bleeding, and death. Finally, the
EMORR2HAGES score demonstrated c-indexes of 0.60 (95%
I: 0.53 to 0.66), 0.60 (95% CI: 0.56 to 0.63), and 0.64 (95% CI:
.57 to 0.71) for the outcome of major bleeding, any clinically
elevant bleeding, and death. Comparison of c-indexes revealed no
tatistically significant differences in the discriminative ability of
he 3 tested scores for the outcomes of major bleeding and death.
The HAS-BLED and HEMORR2HAGES scores were both
uperior to the ATRIA score for the outcome of any clinically
elevant bleeding (HAS-BLED vs. ATRIA, c-index difference
.054, z-score  3, p  0.002; HEMORR2HAGES vs. ATRIA,
-index difference 0.036, z-score  2.3, p  0.02). For the
utcome of any clinically relevant bleeding, using the HAS-BLED
core compared with the ATRIA score correctly (and significantly)
eclassified 11.6% of the population (95% CI: 3.6 to 19.7; p 
.005), whereas using the HEMORR2HAGES score compared
coreshe ATRIA,
–Prediction Scores
Any Clinical
Relevant Bleeding
All-Cause
Mortality
n % n %
31 11.9 5 1.9
142 13 15 1.4
39 20.7 8 4.3
82 17.3 18 3.8
9 9.5 3 3.2
7 19.4 2 5.6
27 25.5 9 8.5
5 45.5 2 18.2
30 8.2 4 1.1
144 12.6 25 2.2
132 20.9 26 4.1
34 26 6 4.6
5 71.4 1 14.3
112 11.3 13 1.3
129 14.9 30 3.5
77 24.8 13 4.2
17 26.2 5 7.7
4 80 1 20
coumarol in Patients With Atrial Fibrillation; ATRIA  anticoagulation
al/liver function, stroke, bleeding history or predisposition, labile INR,IA,tion Sg to t
g Risk
ing
%
2.3
2.1
4.3
4.6
2.1
2.8
8.5
9.1
0.8
3.3
3.9
6.1
0
2
3.9
4.5
6.2
0
r Aceno
al renl abuse, malignancy, older age, reduced platelet count or function,
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January 22, 2013:386–9with the ATRIA score correctly reclassified 4.7% (95% CI: 1.8 to
11.2; p  0.152) of the population, although this finding was
onsignificant.
In a Cox regression analysis, a HAS-BLED score 3 was a
redictor of major bleeding, any clinically relevant bleeding, and
eath, with hazard ratios of 2.3 (95% CI: 1.1 to 5; p  0.028), 2.7
95% CI: 1.9 to 3.8; p  0.001), and 2.8 (95% CI: 1.2 to 6.5; p 
.013), respectively (vs. low-risk category as baseline risk).
This is one of the first comparisons of bleeding risk–prediction
chemes in a cohort of nonwarfarin anticoagulated patients with
F. All 3 bleeding risk–prediction schemes demonstrated similar
odest discriminative performance for the outcome of major
leeding and death. HAS-BLED and HEMORR2HAGES dem-
onstrated superior discriminative performance compared with
ATRIA for the outcome of any clinically relevant bleeding.
Clinically relevant bleeding was the primary safety endpoint in
AMADEUS (which was centrally and blindly adjudicated) and would
be clinically meaningful and highly relevant to patients as well as to
clinicians who ultimately wish to assess, in everyday clinical practice,
those patients who are at risk of important bleeding events. The
modest predictive performance of the scores should be interpreted in
light of the low bleeding risk population in this clinical trial setting,
with the highest categorization into low risk (89.7%) seen for the
ATRIA score.
These results are in accordance with our observations in the
warfarin arm of the AMADEUS cohort (2), suggesting that
despite being initially validated in warfarin-treated populations,
the ATRIA, HAS-BLED, and HEMORR2HAGES schemes
etain their modest predictive performance in patients receiving
ther forms of (nonwarfarin) anticoagulation (1), and that the
AS-BLED and HEMORR2HAGES scores were clearly supe-
rior to the ATRIA score for the outcome of any clinically relevant
bleeding.
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Letters to the Editors
All CAD Is Not CHD,
and All CHD Is Not CAD
I read with great interest the review by Marzilli et al. (1) in a recent
issue of the Journal. The authors make a compelling case that
coronary artery disease (CAD) does not equal ischemic heart
disease (IHD), or vice versa. They also show that angina symptoms
do not always improve after coronary revascularization, whether
surgical- or catheter-based. Certainly every seasoned cardiologist
has seen patients who continue to have IHD symptoms despite
open “native artery” or “bypass graft.” However, many asymptom-
atic patients have received percutaneous coronary intervention
(PCI) or coronary artery bypass grafting (CABG) in the name of
obstructive CAD. Then, there are others who are asymptomatic
and have normal exercise tests despite bypass graft occlusion.
These observations support the essay by Marzilli et al. (1).
Unfortunately, our profession has become catheter laboratory
entric since the day we could see pictures of the live coronary
rtery. The advent of PCI has led to a new medical-industrial
nterprise in which administrators, hospitals, and physicians are
nthusiastic partners. So often one reads about greedy coronary
nterventionalists who have placed stents in arteries with minimal
esions or no lesions at all (2,3). These events have only served to
essen the public’s trust in physicians in general, and cardiologists
n particular. I feel a coronary intervention, such as a PCI, should
e performed only in patients with acute myocardial infarction,
nd CABG should be performed in patients with 2- or 3-vessel
isease with compromised left ventricular function.
We must realize that when we perform PCI or bypass surgery,
e create a new form of coronary lesion that is prone to rapid
therogenesis, and give another disease to the patient, that is,
oagulopathy, which is related to multiple antiplatelet and antico-
gulant drugs. Being true to ourselves and performing a procedure
hen it is needed is the correct, moral, and ethical approach. This
pproach will go a long way in controlling ever-rising healthcare
osts, and restore the public’s trust in their caregivers. The Institute
f Medicine has estimated that our country wastes $750 billion a
ear with inefficient utilization of resources, poor cost control, and
xcessive and unnecessary procedures (4). I urge all readers of the
ournal to read this report.
